经济学能为卫生技术评估带来什么？请不要只是另一种成本效益分析！

What can economics add to health technology assessment? Please not just another cost-effectiveness analysis!

机构信息

Group Leader, University of Heidelberg - Medical School, International Health Economics and Outcomes Research, Department of Tropical Hygiene and Public Health, Im Neuenheimer Feld 324, D-69120 Heidelberg, Germany.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2006 Feb;6(1):19-24. doi: 10.1586/14737167.6.1.19.

DOI:10.1586/14737167.6.1.19

PMID:20528533

Abstract

Evidence based medicine is not only important for clinical practice, but national governments have embraced it through health technology assessment (HTA). HTA combines data from randomized controlled trials (RCT) and observational studies with an economic component (among other issues). HTA, however, is not taking full advantage of economics. This paper presents five areas in which economics may improve not only HTA, but the RCT methods that underpin it. HTA needs to live up to its original agenda of being a interdisciplinary field and draw methods not just from biostatistics, but from a range of discipline, including economics. By focusing only on cost effectiveness analysis (CEA), however, we go nowhere close to fulfilling this potential.

摘要

循证医学不仅对临床实践很重要，而且各国政府也通过卫生技术评估（HTA）来接受它。HTA 将随机对照试验（RCT）和观察性研究的数据与经济因素（以及其他问题）相结合。然而，HTA 并没有充分利用经济学。本文提出了经济学可能不仅改善 HTA，而且还可能改善其基础的 RCT 方法的五个领域。HTA 需要履行其作为跨学科领域的原始议程，不仅要从生物统计学中汲取方法，还要从一系列学科中汲取方法，包括经济学。然而，仅仅关注成本效益分析（CEA），我们就无法实现这一潜力。